STAT Plus: With remdesivir, Gilead finds itself at strategic crossroads, with its reputation (and far more) at stake
Never in modern times have such high hopes for millions of lives rested on one single company.
As the world struggles to fight off Covid-19, Gilead Sciences has been thrust in the spotlight with remdesivir, the antiviral drug that on Friday the Food and Drug Administration gave emergency authorization to treat coronavirus patients. Doctors are already preparing for a surge of requests from potential patients. Anthony Fauci, the nation’s top infectious disease expert, is sounding close to buoyant. The markets are showing signs of recovery. And President Trump, who has vilified the drug industry since before his election, welcomed Gilead CEO Daniel O’Day to the Oval Office.
